These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15627039)

  • 1. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
    Mauss S; Berger F; Schmutz G
    AIDS; 2005 Jan; 19(1):93-5. PubMed ID: 15627039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
    Calza L; Trapani F; Tedeschi S; Piergentili B; Manfredi R; Colangeli V; Viale P
    Scand J Infect Dis; 2011 Aug; 43(8):656-60. PubMed ID: 21453205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
    Viganò A; Zuccotti GV; Martelli L; Giacomet V; Cafarelli L; Borgonovo S; Beretta S; Rombolà G; Mora S
    Clin Drug Investig; 2007; 27(8):573-81. PubMed ID: 17638398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of renal impairment under therapy with tenofovir.
    Jülg BD; Bogner JR; Crispin A; Goebel FD
    AIDS; 2005 Aug; 19(12):1332-3. PubMed ID: 16052093
    [No Abstract]   [Full Text] [Related]  

  • 5. Is tenofovir-related renal toxicity incompletely reversible?
    Campbell LJ; Hamzah L; Post FA
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e95; author reply e95-6. PubMed ID: 21317581
    [No Abstract]   [Full Text] [Related]  

  • 6. Tenofovir-associated decline in renal function.
    Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
    J Infect Dis; 2008 Sep; 198(6):937; author reply 937-8. PubMed ID: 18721062
    [No Abstract]   [Full Text] [Related]  

  • 7. A clinical prediction score for targeted creatinine testing before initiating tenofovir-based antiretroviral treatment in Cambodia.
    van Griensven J; Phirum L; Thai S; Buyze J; Lynen L
    J Acquir Immune Defic Syndr; 2014 Apr; 65(4):e150-2. PubMed ID: 24121759
    [No Abstract]   [Full Text] [Related]  

  • 8. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
    Andrade-Fuentes K; Mata-Marín JA; López-De León JI; Manjarrez-Téllez B; Ramírez JL; Gaytan-Martínez J
    AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is phosphatemia the best tool to monitor renal tenofovir toxicity?
    Essig M; Duval X; Kaied FA; Iordache L; Gervais A; Longuet P; Blanchet F; Peytavin G; Leport C
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):256-8. PubMed ID: 17895770
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of tenofovir exposure with kidney disease risk in HIV infection.
    Scherzer R; Estrella M; Li Y; Choi AI; Deeks SG; Grunfeld C; Shlipak MG
    AIDS; 2012 Apr; 26(7):867-75. PubMed ID: 22313955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
    Jabłonowska E; Wójcik K; Piekarska A
    AIDS Res Hum Retroviruses; 2014 Apr; 30(4):363-9. PubMed ID: 24164392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir-associated renal and bone toxicity.
    Woodward CL; Hall AM; Williams IG; Madge S; Copas A; Nair D; Edwards SG; Johnson MA; Connolly JO
    HIV Med; 2009 Sep; 10(8):482-7. PubMed ID: 19459988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
    Herlitz LC; Mohan S; Stokes MB; Radhakrishnan J; D'Agati VD; Markowitz GS
    Kidney Int; 2010 Dec; 78(11):1171-7. PubMed ID: 20811330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
    AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
    Kinai E; Hanabusa H
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir-associated proteinuria.
    Kelly MD; Gibson A; Bartlett H; Rowling D; Patten J
    AIDS; 2013 Jan; 27(3):479-81. PubMed ID: 22874515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up.
    Laprise C; Baril JG; Dufresne S; Trottier H
    Clin Infect Dis; 2013 Feb; 56(4):567-75. PubMed ID: 23143096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir.
    Labarga P; Barreiro P; Martin-Carbonero L; Rodriguez-Novoa S; Solera C; Medrano J; Rivas P; Albalater M; Blanco F; Moreno V; Vispo E; Soriano V
    AIDS; 2009 Mar; 23(6):689-96. PubMed ID: 19262355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.